Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

Conditions

• Cardiovascular Diseases
• Dyslipidemias
• Statin Adverse Reaction
• Pharmacogenic Myopathy

Interventions

• OTHER: Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
• OTHER: Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines
• OTHER: Standard of Care (SoC) dosing of atorvastatin
• OTHER: Standard of Care (SoC) dosing of simvastatin
• OTHER: Standard of Care (SoC) dosing of pitavastatin
• OTHER: Standard of Care (SoC) dosing of rosuvastatin
• OTHER: Standard of Care (SoC) dosing of prasavastatin
• OTHER: Standard of Care (SoC) dosing of lovastatin
• OTHER: Standard of Care (SoC) dosing of fluvastatin

Sponsor

Instituto de Investigación Hospital Universitario La Paz

Collaborators

• [object Object]